Cytori Therapeutics (NASDAQ: CYTX) today reports its first quarter 2013
financial results and provides updates on clinical development and
commercialization activities.
... read more
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its
first quarter financial results and business update on Thursday, May 9,
2013 at 5:00 PM Eastern Time.
... read more
Cytori
Therapeutics (NASDAQ: CYTX) received US Patent No. 8,404,229 (the
‘229 patent) for methods of treating renal diseases using
adipose-derived regenerative cells ... read more
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its
fourth quarter and year end financial results and business update on
Thursday, March 7, 2013 at 5:00 ... read more
Cytori Therapeutics (NASDAQ: CYTX) has appointed Steven Kesten, MD, as
Executive Vice President and Chief Medical Officer. In this role, Dr.
Kesten will lead global clinical development operations ... read more
Cytori Therapeutics (NASDAQ: CYTX) has received a CE Mark in Europe for
Intravase®, a reagent intended to be used with Cytori’s
Celution® System for preparing safe and optimized ... read more
SAN DIEGO, CA -- (Marketwire) -- 11/11/10 -- Cytori Therapeutics (NASDAQ: CYTX) will be hosting an investor teach-in on cardiac cell therapy on Tuesday, November 16 from 7:00-8:00 AM CT (8:00-9:00 AM ET) from the American Heart Association meeting in Chicago. The goal is to help investors evaluate ... read more